Research programme: complement factor D inhibitors - Achillion Pharmaceuticals

Drug Profile

Research programme: complement factor D inhibitors - Achillion Pharmaceuticals

Alternative Names: ACH 0145228; ACH 5228; ACH CFDIS

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Autoimmune disorders; Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Autoimmune disorders in USA (PO) (Achillion pipeline, November 2017)
  • 03 Nov 2017 Achillion Pharmaceuticals plans a phase I trial for Autoimmune disorders (In volunteers) in New Zealand in November 2017 (ACTRN12617001521314p)
  • 21 Mar 2017 Achillion Pharmaceuticals has issued and pending patents for complement factor-D inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top